Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
JMIR Mhealth Uhealth ; 7(3): e11933, 2019 03 07.
Article in English | MEDLINE | ID: mdl-30843865

ABSTRACT

BACKGROUND: Technology has long been used to carry out self-management as well as to improve adherence to treatment in people with diabetes. However, most technology-based apps do not meet the basic requirements for engaging patients. OBJECTIVE: This study aimed to evaluate the effect of use frequency of a diabetes management app on glycemic control. METHODS: Overall, 2 analyses were performed. The first consisted of an examination of the reduction of blood glucose (BG) mean, using a randomly selected group of 211 users of the SocialDiabetes app (SDA). BG levels at baseline, month 3, and month 6 were calculated using the intercept of a regression model based on data from months 1, 4, and 7, respectively. In the second analysis, the impact of low and high BG risk was examined. A total of 2692 users logging SDA ≥5 days/month for ≥6 months were analyzed. The highest quartile regarding low blood glucose index (LBGI) and high blood glucose index (HBGI) at baseline (t1) was selected (n=74 for group A; n=440 for group B). Changes in HBGI and LBGI at month 6 (t2) were analyzed. RESULTS: For analysis 1, baseline BG results for type 1 diabetes mellitus (T1DM) groups A and B were 213.61 (SD 31.57) mg/dL and 206.43 (SD 18.65) mg/dL, respectively, which decreased at month 6 to 175.15 (SD 37.88) mg/dL and 180.6 (SD 40.47) mg/dL, respectively. For type 2 diabetes mellitus (T2DM), baseline BG was 218.77 (SD 40.18) mg/dL and 232.55 (SD 46.78) mg/dL, respectively, which decreased at month 6 to 160.51 (SD 39.32) mg/dL and 173.14 (SD 52.81) mg/dL for groups A and B, respectively. This represents a reduction of estimated A1c (eA1c) of approximately 1.3% (P<.001) and 0.9% (P=.001) for T1DM groups A and B, respectively, and 2% (P<.001) for both A and B T2DM groups, respectively. For analysis 2, T1DM baseline LBGI values for groups A and B were 5.2 (SD 3.9) and 4.4 (SD 2.3), respectively, which decreased at t2 to 3.4 (SD 3.3) and 3.4 (SD 1.9), respectively; this was a reduction of 34.6% (P=.005) and 22.7% (P=.02), respectively. Baseline HBGI values for groups A and B were 12.6 (SD 4.3) and 10.6 (SD 4.03), respectively, which decreased at t2 to 9.0 (SD 6.5) and 8.6 (SD 4.7), respectively; this was a reduction of 30% (P=.001) and 22% (P=.003), respectively. CONCLUSIONS: A significant reduction in BG was found in all groups, independent of the use frequency of the app. Better outcomes were found for T2DM patients. A significant reduction in LBGI and HBGI was found in all groups, regardless of the use frequency of the app. LBGI and HBGI indices of both groups tend to have similar values after 6 months of app use.


Subject(s)
Blood Glucose Self-Monitoring/instrumentation , Diabetes Mellitus/therapy , Mobile Applications/standards , Adult , Blood Glucose/analysis , Blood Glucose Self-Monitoring/methods , Blood Glucose Self-Monitoring/psychology , Diabetes Mellitus/psychology , Evaluation Studies as Topic , Female , Humans , Hyperglycemia/blood , Hyperglycemia/diagnosis , Hypoglycemia/blood , Hypoglycemia/diagnosis , Male , Middle Aged , Mobile Applications/statistics & numerical data , Self-Management/methods , Self-Management/psychology
2.
Article in English | MEDLINE | ID: mdl-27644067

ABSTRACT

This paper presents a methodological review of models for predicting blood glucose (BG) concentration, risks and BG events. The surveyed models are classified into three categories, and they are presented in summary tables containing the most relevant data regarding the experimental setup for fitting and testing each model as well as the input signals and the performance metrics. Each category exhibits trends that are presented and discussed. This document aims to be a compact guide to determine the modeling options that are currently being exploited for personalized BG prediction.


Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 1/blood , Humans , Insulin/blood
3.
J Diabetes Sci Technol ; 6(5): 1131-41, 2012 Sep 01.
Article in English | MEDLINE | ID: mdl-23063040

ABSTRACT

BACKGROUND: The popularity of continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, as a way to deliver insulin more physiologically and achieve better glycemic control in diabetes patients has increased. Despite the substantiated therapeutic advantages of using CSII, its use has also been associated with an increased risk of technical malfunctioning of the device, which leads to an increased risk of acute metabolic complications, such as diabetic ketoacidosis. Current insulin pumps already incorporate systems to detect some types of faults, such as obstructions in the infusion set, but are not able to detect other types of fault such as the disconnection or leakage of the infusion set. METHODS: In this article, we propose utilizing a validated robust model-based fault detection technique, based on interval analysis, for detecting disconnections of the insulin infusion set. For this purpose, a previously validated metabolic model of glucose regulation in type 1 diabetes mellitus (T1DM) and a continuous glucose monitoring device were used. As a first step to assess the performance of the presented fault detection system, a Food and Drug Administration-accepted T1DM simulator was employed. RESULTS: Of the 100 in silico tests (10 scenarios on 10 subjects), only two false negatives and one false positive occurred. All faults were detected before plasma glucose concentration reached 300 mg/dl, with a mean plasma glucose detection value of 163 mg/dl and a mean detection time of 200 min. CONCLUSIONS: Interval model-based fault detection has been proven (in silico) to be an effective tool for detecting disconnection faults in sensor-augmented CSII systems. Proper quantification of the uncertainty associated with the employed model has been observed to be crucial for the good performance of the proposed approach.


Subject(s)
Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/drug therapy , Equipment Failure Analysis/methods , Insulin Infusion Systems , Insulin/administration & dosage , Medication Errors/prevention & control , Adult , Algorithms , Blood Glucose Self-Monitoring/instrumentation , Blood Glucose Self-Monitoring/standards , Computer Simulation , Diagnostic Errors/prevention & control , Humans , Hyperglycemia/blood , Hyperglycemia/diagnosis , Hyperglycemia/prevention & control , Hypoglycemia/blood , Hypoglycemia/diagnosis , Hypoglycemia/prevention & control , Hypoglycemic Agents/administration & dosage , Insulin Infusion Systems/standards , Models, Biological , Models, Theoretical , Reference Values
4.
J Diabetes Sci Technol ; 6(2): 345-7, 2012 Mar 01.
Article in English | MEDLINE | ID: mdl-22538145

ABSTRACT

Since the early 2000s, there has been an exponentially increasing development of new diabetes-applied technology, such as continuous glucose monitoring, bolus calculators, and "smart" pumps, with the expectation of partially overcoming clinical inertia and low patient compliance. However, its long-term efficacy in glucose control has not been unequivocally proven. In this issue of Journal of Diabetes Science and Technology, Sussman and colleagues evaluated a tool for the calculation of the prandial insulin dose. A total of 205 insulin-treated patients were asked to compute a bolus dose in two simulated conditions either manually or with the bolus calculator built into the FreeStyle InsuLinx meter, revealing the high frequency of wrong calculations when performed manually. Although the clinical impact of this study is limited, it highlights the potential implications of low diabetesrelated numeracy in poor glycemic control. Educational programs aiming to increase patients' empowerment and caregivers' knowledge are needed in order to get full benefit of the technology.


Subject(s)
Blood Glucose Self-Monitoring/instrumentation , Blood Glucose/drug effects , Diabetes Mellitus/diagnosis , Diabetes Mellitus/drug therapy , Drug Dosage Calculations , Hypoglycemic Agents/administration & dosage , Insulin, Short-Acting/administration & dosage , Female , Humans , Male
5.
J Diabetes Sci Technol ; 6(6): 1420-8, 2012 Nov 01.
Article in English | MEDLINE | ID: mdl-23294789

ABSTRACT

OBJECTIVE: Set-inversion-based prandial insulin delivery is a new model-based bolus advisor for postprandial glucose control in type 1 diabetes mellitus (T1DM). It automatically coordinates the values of basal-bolus insulin to be infused during the postprandial period so as to achieve some predefined control objectives. However, the method requires an excessive computation time to compute the solution set of feasible insulin profiles, which impedes its integration into an insulin pump. In this work, a new algorithm is presented, which reduces computation time significantly and enables the integration of this new bolus advisor into current processing features of smart insulin pumps. METHODS: A new strategy was implemented that focused on finding the combined basal-bolus solution of interest rather than an extensive search of the feasible set of solutions. Analysis of interval simulations, inclusion of physiological assumptions, and search domain contractions were used. Data from six real patients with T1DM were used to compare the performance between the optimized and the conventional computations. RESULTS: In all cases, the optimized version yielded the basal-bolus combination recommended by the conventional method and in only 0.032% of the computation time. Simulations show that the mean number of iterations for the optimized computation requires approximately 3.59 s at 20 MHz processing power, in line with current features of smart pumps. CONCLUSIONS: A computationally efficient method for basal-bolus coordination in postprandial glucose control has been presented and tested. The results indicate that an embedded algorithm within smart insulin pumps is now feasible. Nonetheless, we acknowledge that a clinical trial will be needed in order to justify this claim.


Subject(s)
Algorithms , Diabetes Mellitus, Type 1/drug therapy , Hypoglycemic Agents/administration & dosage , Insulin Infusion Systems , Insulin/administration & dosage , Adult , Blood Glucose Self-Monitoring/methods , Female , Humans , Hyperglycemia/prevention & control , Male , Postprandial Period
6.
J Diabetes Sci Technol ; 4(6): 1424-37, 2010 Nov 01.
Article in English | MEDLINE | ID: mdl-21129338

ABSTRACT

BACKGROUND: Achieving good postprandial glycemic control, without triggering hypoglycemia events, is a challenge of treatment strategies for type 1 diabetes subjects. Continuous subcutaneous insulin infusion, the gold standard of therapy, is based on heuristic adjustments of both basal and prandial insulin. Some tools, such as bolus calculators, are available to aid patients in selecting a meal-related insulin dose. However, they are still based on empiric parameters such as the insulin-to-carbohydrate ratio and on the physicians' and patients' ability to fit bolus mode to meal composition. METHODS: In this article, a nonheuristic method for assessment of prandial insulin administration is presented and evaluated. An algorithm based on set inversion via interval analysis is used to coordinate basal and bolus insulin infusions to deal with postprandial glucose excursions. The evaluation is carried out through an in silico study using the 30 virtual patients available in the educational version of the Food and Drug Administration-accepted University of Virginia simulator. Results obtained using the standard bolus strategy and different coordinated basal-bolus solutions provided by the algorithm are compared. RESULTS: Coordinated basal-bolus solutions improve postprandial glucose performance in most cases, mainly in terms of reducing hypoglycemia risk, but also increasing the percentage of time in normoglycemia. Moreover, glycemic variability is reduced considerably by using these innovative solutions. CONCLUSIONS: The algorithm presented here is a robust nonheuristic alternative to deal with postprandial glycemic control. It is shown as a powerful tool that could be integrated in future smart insulin pumps.


Subject(s)
Blood Glucose/drug effects , Computer Simulation , Diabetes Mellitus, Type 1/drug therapy , Hypoglycemic Agents/administration & dosage , Insulin Infusion Systems , Insulin/administration & dosage , Models, Biological , Adolescent , Algorithms , Automation , Blood Glucose/metabolism , Child , Diabetes Mellitus, Type 1/blood , Drug Dosage Calculations , Humans , Hypoglycemia/blood , Hypoglycemia/chemically induced , Hypoglycemia/prevention & control , Hypoglycemic Agents/adverse effects , Insulin/adverse effects , Middle Aged , Postprandial Period , Time Factors , Treatment Outcome
7.
J Diabetes Sci Technol ; 3(1): 89-97, 2009 Jan.
Article in English | MEDLINE | ID: mdl-20046653

ABSTRACT

BACKGROUND: Basal and bolus insulin determination in intensive insulin therapy for type 1 diabetes mellitus (T1DM) are currently considered independently of each other. A new strategy that coordinates basal and bolus insulin infusion to cope with postprandial glycemia in pump therapy is proposed. Superior performance of this new strategy is demonstrated through a formal analysis of attainable performances in an in silico study. METHODS: The set inversion via interval analysis algorithm has been applied to obtain the feasible set of basal and bolus doses that, for a given meal, mathematically guarantee a postprandial response fulfilling the International Diabetes Federation (IDF) guidelines (i.e., no hypoglycemia and 2 h postprandial glucose below 140 mg/dl). Hypoglycemia has been defined as a glucose value below 70 mg/dl. A 5 h time horizon has been considered for a 70 kg in silico T1DM subject consuming meals in the range of 30 to 80 g of carbohydrates. RESULTS: The computed feasible sets demonstrate that current separated basal/bolus strategy dramatically limits the attainable performance. For a nominal basal of 0.8 IU/h leading to a basal glucose of approximately 100 mg/dl, IDF guidelines cannot be fulfilled for meals greater than 50 g of carbohydrates, independent of the bolus insulin computed. However, coordinating the basal and bolus insulin delivery can achieve this. A decrement of basal insulin during the postprandial period is required together with an increase in bolus insulin, in appropriate percentages, which is meal dependent. After 3 h, basal insulin can be restored to its nominal value. CONCLUSIONS: The new strategy meets IDF guidelines in a typical day, contrary to the standard basal/bolus strategy, yielding a mean 2 h postprandial glucose reduction of 36.4 mg/dl without late hypoglycemia. The application of interval analysis for the computation of feasible sets is demonstrated to be a powerful tool for the analysis of attainable performance in glucose control.


Subject(s)
Blood Glucose/drug effects , Diabetes Mellitus, Type 1/drug therapy , Hypoglycemic Agents/administration & dosage , Insulin Infusion Systems , Insulin/administration & dosage , Models, Theoretical , Blood Glucose/metabolism , Diabetes Mellitus, Type 1/metabolism , Humans , Hypoglycemic Agents/metabolism , Insulin/metabolism
8.
J Diabetes Sci Technol ; 3(4): 895-902, 2009 Jul 01.
Article in English | MEDLINE | ID: mdl-20144339

ABSTRACT

OBJECTIVE: The objective of this article was to develop a methodology to quantify the risk of suffering different grades of hypo- and hyperglycemia episodes in the postprandial state. METHODS: Interval predictions of patient postprandial glucose were performed during a 5-hour period after a meal for a set of 3315 scenarios. Uncertainty in the patient's insulin sensitivities and carbohydrate (CHO) contents of the planned meal was considered. A normalized area under the curve of the worst-case predicted glucose excursion for severe and mild hypo- and hyperglycemia glucose ranges was obtained and weighted accordingly to their importance. As a result, a comprehensive risk measure was obtained. A reference model of preprandial glucose values representing the behavior in different ranges was chosen by a xi(2) test. The relationship between the computed risk index and the probability of occurrence of events was analyzed for these reference models through 19,500 Monte Carlo simulations. RESULTS: The obtained reference models for each preprandial glucose range were 100, 160, and 220 mg/dl. A relationship between the risk index ranges <10, 10-60, 60-120, and >120 and the probability of occurrence of mild and severe postprandial hyper- and hypoglycemia can be derived. CONCLUSIONS: When intrapatient variability and uncertainty in the CHO content of the meal are considered, a safer prediction of possible hyper- and hypoglycemia episodes induced by the tested insulin therapy can be calculated.


Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 1/blood , Hyperglycemia/blood , Hypoglycemia/blood , Postprandial Period , Chi-Square Distribution , Computer Simulation , Humans , Individuality , Monte Carlo Method , Reference Values , Risk
SELECTION OF CITATIONS
SEARCH DETAIL
...